Z Squared (ZSQR) Q1 2025 earnings summary

Executive summary

• Focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases, and expanding technology offerings with AI-powered marketing and automation tools.

• Operates through two segments: Biotechnology (non-revenue generating, R&D focus) and Technology (acquisition of tech assets, minimal revenue).

• Completed a 20-1 reverse stock split effective December 31, 2024.

• Entered into a merger agreement to spin out biotechnology operations and merge with Z Squared, Inc.

Financial highlights

• Cash increased to $4.3M as of March 31, 2025, from $1.0M at March 31, 2024.

• Net loss for Q1 2025 was $3.4M, compared to $3.0M in Q1 2024.

• Revenue for Q1 2025 was $62.9K, flat year-over-year.

• Operating expenses rose to $4.1M in Q1 2025 from $2.9M in Q1 2024, driven by higher stock-based compensation and professional services.

• Accumulated deficit reached $101.7M as of March 31, 2025.

Outlook and guidance

• Management does not expect significant revenue for at least the next two years as drug development continues.

• Plans to raise additional capital through equity or debt to sustain operations until profitability is achieved.

• Strategic focus on advancing cell therapy platforms and expanding technology segment offerings.